Axsome Therapeutics, Inc. (AXSM) Touches $3.30 Low on Jan, 14; Dominion Midstream Partners Has 1.07 Sentiment

January 14, 2018 - By Peter Erickson

Dominion Energy Midstream Partners, LP owns liquefied natural gas import, storage, regasification, and transportation assets. The company has market cap of $3.15 billion. It owns and operates LNG facility located on the Chesapeake Bay in Lusby, Maryland; and has approximately 136 miles of natural gas pipeline that connects its LNG facility to interstate natural gas pipelines. It has a 22.72 P/E ratio. The firm also operates an interstate pipeline in South Carolina and southeastern Georgia comprising natural gas system consisting of approximately 1,500 miles of transmission pipeline and 5 compressor stations with approximately 38,700 installed compressor horsepower.

The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) reached all time low today, Jan, 14 and still has $3.20 target or 3.00% below today’s $3.30 share price. This indicates more downside for the $83.98 million company. This technical setup was reported by Barchart.com. If the $3.20 PT is reached, the company will be worth $2.52 million less. The stock decreased 2.94% or $0.1 during the last trading session, reaching $3.3. About 1.34 million shares traded or 294.88% up from the average. Axsome Therapeutics, Inc. (NASDAQ:AXSM) has declined 59.08% since January 14, 2017 and is downtrending. It has underperformed by 75.78% the S&P500.

The stock decreased 1.71% or $0.55 during the last trading session, reaching $31.65. About 247,946 shares traded or 42.00% up from the average. Dominion Energy Midstream Partners, LP (DM) has risen 2.59% since January 14, 2017 and is uptrending. It has underperformed by 14.11% the S&P500.

Chickasaw Capital Management Llc holds 3.69% of its portfolio in Dominion Energy Midstream Partners, LP for 5.38 million shares. Spirit Of America Management Corp Ny owns 794,981 shares or 2.69% of their US portfolio. Moreover, Yorkville Capital Management Llc has 2.62% invested in the company for 70,710 shares. The Wisconsin-based A. D. Beadell Investment Counsel Inc. has invested 2.52% in the stock. Nbw Capital Llc, a Massachusetts-based fund reported 269,022 shares.

Ratings analysis reveals 67% of Dominion Midstream’s analysts are positive. Out of 3 Wall Street analysts rating Dominion Midstream, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $29.0 while the high is $30.0. The stock’s average target of $29.50 is -6.79% below today’s ($31.65) share price. DM was included in 3 notes of analysts from August 18, 2016. The stock of Dominion Energy Midstream Partners, LP (NYSE:DM) earned “Buy” rating by Stifel Nicolaus on Wednesday, September 14. Mizuho initiated Dominion Energy Midstream Partners, LP (NYSE:DM) on Friday, September 30 with “Buy” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, August 18.

Analysts await Dominion Energy Midstream Partners, LP (NYSE:DM) to report earnings on February, 7. They expect $0.38 earnings per share, 0.00% or $0.00 from last year’s $0.38 per share. DM’s profit will be $37.80 million for 20.82 P/E if the $0.38 EPS becomes a reality. After $0.33 actual earnings per share reported by Dominion Energy Midstream Partners, LP for the previous quarter, Wall Street now forecasts 15.15% EPS growth.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system disorders. The company has market cap of $83.98 million. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It currently has negative earnings. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain.

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) earned “Buy” rating by Brean Capital on Monday, October 3. The firm has “Buy” rating by Ladenburg Thalmann given on Monday, December 14. The company was initiated on Tuesday, December 15 by Cantor Fitzgerald.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>